通心络胶囊对急性脑梗死患者血浆溶血磷脂酸含量的影响

目的 探讨通心络胶囊对急性脑梗死患者血浆溶血磷脂酸(LPA)的影响及其治疗作用机制,分析达到预防脑梗死复发效果所需强化治疗的最短时间.方法 选取经临床和CT/MRI确诊的发病72 h内的急性脑梗死患者70例,采用随机数字表法分为治疗组和对照组.2组患者均给予常规治疗,包括阿司匹林片11服,每次100mg,每天1次.治疗组加用通心络胶囊口服,每次4粒,每天3次,连服60d.全部患者于发病72 h内及治疗30、60 d时测定血浆LPA含量.观察通心络胶囊对脑梗步匕患者血浆LPA含量变化的影响,并随访2个月内腩梗死的复发率.结果 2组患者治疗后较治疗前血浆LPA含量均明显降低,治疗组更为明显.治疗30 d时血浆LPA含量则已降至正常,与对照组比较,差异有统计学意义(P<0.05).治疗组治疗60 d内脑梗死复发率较对照组明显降低,差异有统汁学意义(P<0.05).结论 通心络胶囊可以显著降低脑梗死患者血浆LPA含量,与阿司匹林合用可能有较好的预防脑梗死复发的效果.建议急性脑梗死发病后的强化治疗时间不少于1个月.

Influence of Tongxinluo capsules on plasma levels of lysophosphatidic acid in patients with acute cerebral infarction

Objective To investigate the changes of plasma levels of lysophosphatidic acid (LPA) in the patients with acute cerebral infarction and to observe whether the treatment with Tongxinluo capsules would reduce the plasma LPA levels of the patients with acute cerebral infarction. Methods A total of 70 patients were randomly divided into treatment group and control group. Patients in treatment group were treated with normal method, aspirin (100 mg once a day) and Tongxinluo capsules (4 pills for 3 times per day for 60 d). Patients in control group were treated with only normal method and aspirin (100 mg once a day). Plasma LPA levels were measured consecutively in all patients before treatment, 30 d and 60 d after treatment. The effects of Tongxinluo capsules on plasma LPA levels were observed, and the recurrence rate of cerebral infarction was recorded within 2 months. Results The average levels of plasma LPA in the 2 groups were decreased obviously after the treatments (P<0.05), and the changes of plasma LPA levels in treatment group were significant after treatment for 30 d compared with those in control group (P<0.05). The recurrence rate of cerebral infarction in treatment group was lower than that in control group. Conclusions The plasma LPA levels in the patients with acute cerebral infarction can be decreased significantly after treatment with Tongxinluo capsules. Combined treatment of Tongxinluo capsules with aspirin may reduce the plasma LPA levels and the frequency of cerebral infarction events better.